Blue Owl Capital

Blue Owl Capital Expands into Real Estate Finance with Acquisition of Prima Capital Advisors

Retrieved on: 
Tuesday, April 9, 2024
Real estate, HOM, Culture, Morgan Stanley, LLP, Acquisition, Scotiabank, Investment banking, Pleasure, Earnout, GIC, Blue Owl Capital, Pillsbury Winthrop Shaw Pittman, Wells Fargo, Kirkland & Ellis, J.P. Morgan & Co.

NEW YORK, April 9, 2024 /PRNewswire/ -- Blue Owl Capital Inc. ("Blue Owl") (NYSE: OWL), a leading alternative asset manager, announced today the creation of Blue Owl's Real Estate Finance strategy with the acquisition of Prima Capital Advisors ("Prima") for the aggregate consideration of $170 million.

Key Points: 
  • NEW YORK, April 9, 2024 /PRNewswire/ -- Blue Owl Capital Inc. ("Blue Owl") (NYSE: OWL), a leading alternative asset manager, announced today the creation of Blue Owl's Real Estate Finance strategy with the acquisition of Prima Capital Advisors ("Prima") for the aggregate consideration of $170 million.
  • Prima, founded in 1992 by Gregory White, is a real estate lender focused primarily on investing in commercial mortgage-backed securities.
  • Blue Owl also announced that Jesse Hom, previously Global Head of Real Estate Credit at GIC, will join Blue Owl to lead the newly created Real Estate Finance strategy and serve as Chief Investment Officer for Blue Owl's Real Estate platform, reporting directly to Marc Zahr, Co-President of Blue Owl and Head of Real Estate.
  • Blue Owl Co-CEOs Doug Ostrover and Marc Lipschultz said: "This acquisition of Prima represents a further expansion of Blue Owl's suite of capital solutions, adding a differentiated and high-quality real estate lending capability and further diversifying our real estate platform.

Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives

Retrieved on: 
Wednesday, April 3, 2024
Research, Finance, Clinical Trials, Professional Services, Biotechnology, Health, General Health, Science, Oncology, OrbiMed, Drug discovery, Patient, Cancer, Sachs, Blue Owl Capital, Protein, Medicine, Richard Driehaus, Therapy, Partner

Alterome Therapeutics, Inc. , a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the closing of a $132 million Series B financing.

Key Points: 
  • Alterome Therapeutics, Inc. , a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the closing of a $132 million Series B financing.
  • The financing was led by Goldman Sachs Alternatives, with participation by Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, and existing investors Orbimed, Nextech Invest, Vida Ventures, Boxer Capital, and Colt Ventures.
  • Concurrent with the financing, Josh Richardson, M.D., a Managing Director within Life Sciences Investing at Goldman Sachs Alternatives, and Uwe Schoenbeck, a Partner at Canaan Partners, were named to the Board of Directors.
  • “Alterome is advancing an exciting portfolio of therapies targeting validated oncogenic drivers, with clear paths to early clinical signals,” said Dr. Josh Richardson, Managing Director within Life Sciences Investing at Goldman Sachs Alternatives.

KBRA Assigns Rating to Blue Owl Technology Finance Corp. II's $700 Million Senior Unsecured Notes

Retrieved on: 
Thursday, March 28, 2024
Banking, Professional Services, Insurance, Finance, Risk management, Growth, BBB, Risk, Application software, System, Business Development Company, BDC, KBRA, Diversification, Blue Owl Capital, Investment, AUM, RIC, OTF, Bank

KBRA assigns a rating of BBB to Blue Owl Technology Finance Corporation II’s (“OTF II” or “the company”) $700 million, 6.750% senior unsecured notes due 2029.

Key Points: 
  • KBRA assigns a rating of BBB to Blue Owl Technology Finance Corporation II’s (“OTF II” or “the company”) $700 million, 6.750% senior unsecured notes due 2029.
  • OTF II’s growth capital portfolio comprised 13.2% of the investment portfolio and had a weighted average enterprise value of $12.8 billion.
  • The company is managed by Blue Owl Technology Credit Advisors II LLC, an affiliate Blue Owl Capital, Inc., which had approximately $165+ billion of AUM as of December 31, 2023.
  • The company’s investment strategy coincides with the strategy of Blue Owl Technology Finance Corp. (KBRA Issuer/Senior Unsecured Debt ratings of BBB/Stable Outlook) and Blue Owl Technology Income Corp. (KBRA Issuer/Senior Unsecured Debt ratings of BBB/Stable Outlook).

Blue Owl Capital Inc. to Announce First Quarter 2024 Results

Retrieved on: 
Thursday, April 4, 2024
Blue Owl Capital, Webcast, Conference, Person

NEW YORK, April 4, 2024 /PRNewswire/ -- Blue Owl Capital Inc. (NYSE: OWL) ("Blue Owl") today announced it will release its financial results for the first quarter ended March 31, 2024 on Thursday, May 2, 2024 before market open.

Key Points: 
  • NEW YORK, April 4, 2024 /PRNewswire/ -- Blue Owl Capital Inc. (NYSE: OWL) ("Blue Owl") today announced it will release its financial results for the first quarter ended March 31, 2024 on Thursday, May 2, 2024 before market open.
  • Blue Owl invites all interested persons to its webcast / conference call at 10 a.m. Eastern Time on May 2 to discuss its results.
  • Participants are also invited to access the conference call by dialing one of the following numbers:
    All callers will need to enter the Conference ID followed by the # sign and reference "Blue Owl Capital" once connected with the operator.
  • An archived replay will be available via a webcast link located on the Investor Resources section of Blue Owl's website.

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

Retrieved on: 
Friday, March 8, 2024
Acquisition, Roche, Blue Owl Capital, License, G&A, CVR, NDA, Video game

EMERYVILLE, Calif., March 08, 2024 (GLOBE NEWSWIRE) --  XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, reported its fourth quarter and full year 2023 financial results and highlighted portfolio activities expected to drive long-term shareholder value.

Key Points: 
  • XOMA recorded total revenues of $1.8 million and $4.8 million for the fourth quarter and full year of 2023, respectively.
  • General and administrative (“G&A”) expenses were $7.3 million for the fourth quarter and $25.6 million for the full year of 2023.
  • In the fourth quarter of 2023, G&A expenses included $2.6 million in non-cash stock-based compensation expense, compared with $1.0 million in the fourth quarter of 2022.
  • In 2023, net loss for the fourth quarter and year ended December 31, 2023, was $20.1 million and $40.8 million, respectively.

Blue Owl Capital Inc. to Present at the Bank of America 2024 Financial Services Conference

Retrieved on: 
Tuesday, February 13, 2024
Bank, Blue Owl Capital, Conference

NEW YORK, Feb. 13, 2024 /PRNewswire/ -- Blue Owl Capital Inc. (NYSE: OWL) ("Blue Owl") today announced that Marc Lipschultz, co-CEO, will present at the Bank of America 2024 Financial Services Conference on Thursday, February 22, 2024 at 11:20 am ET.

Key Points: 
  • NEW YORK, Feb. 13, 2024 /PRNewswire/ -- Blue Owl Capital Inc. (NYSE: OWL) ("Blue Owl") today announced that Marc Lipschultz, co-CEO, will present at the Bank of America 2024 Financial Services Conference on Thursday, February 22, 2024 at 11:20 am ET.
  • A live webcast of the presentation will be broadcast live on the Investor Resources section of Blue Owl's website at www.blueowl.com .
  • For those unable to listen to the live webcast, a replay will be available on Blue Owl's website shortly after the event.

STORE Capital Marks Anniversary of Privatization With Logo Refresh

Retrieved on: 
Tuesday, February 6, 2024
Commercial Building & Real Estate, Construction & Property, REIT, Partnership, Multimedia, Blue Owl Capital, Privatization, GIC, Store Capital

STORE Capital LLC (“STORE”, “STORE Capital” or the “Company”), an internally managed net-lease real estate investment trust (REIT) that invests in Single Tenant Operational Real Estate, today revealed a refreshed logo.

Key Points: 
  • STORE Capital LLC (“STORE”, “STORE Capital” or the “Company”), an internally managed net-lease real estate investment trust (REIT) that invests in Single Tenant Operational Real Estate, today revealed a refreshed logo.
  • Last February, STORE Capital was taken private by GIC, a global institutional investor, in partnership with funds managed by Blue Owl Capital.
  • View the full release here: https://www.businesswire.com/news/home/20240205202813/en/
    The refreshed STORE Capital logo centers on a new logo mark, comprised of two individual design elements, which join together to form the ‘O’ in “STORE.” This purposeful design choice was made to symbolize the power of forged relationships.
  • It’s fitting to reveal our refreshed logo on the 1-year anniversary of the privatization, and we look forward to what the future holds.”

BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines

Retrieved on: 
Thursday, January 18, 2024
DSM-IV codes, Patient, CPP, Investment, Cooley LLP, CFA, PALO, Latham & Watkins, Morgan Stanley, Blue Owl Capital, Cancer, FDA, CPP Investment Board, Doctor of Philosophy, CPPIB, Pharmaceutical industry

PALO ALTO, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced strategic financing from Blue Owl Capital (Blue Owl) and Canada Pension Plan Investment Board (CPP Investments), through a wholly owned subsidiary (CPPIB Credit) of CPPIB Credit Investments Inc., bringing in capital of up to $1.25 billion.

Key Points: 
  • “Acoramidis has demonstrated an impressive and differentiated clinical profile, and we believe it will be an important advancement in the treatment of ATTR-CM.
  • Further, BridgeBio’s promising pipeline of late-stage targeted rare disease therapies address critical unmet needs in these underserved populations.
  • “Investments in leading therapies also help to diversify our capital allocations to income streams that are typically uncorrelated to the broader capital markets.”
    Morgan Stanley & Co. LLC acted as sole structuring agent on the transactions.
  • Latham & Watkins served as legal advisor to BridgeBio and Cooley LLP advised Blue Owl.

KBRA Assigns Rating to Blue Owl Credit Income Corp.'s $750 Million 6.65% Senior Unsecured Notes due 2031

Retrieved on: 
Monday, January 29, 2024
Professional Services, Finance, OCIC, BDC, Business Development Company, KBRA, BBB, Blue Owl Capital, Risk, Investment, Risk management, Lisp (programming language), AUM, RIC, Growth

KBRA assigns a rating of BBB to Blue Owl Credit Income Corp.'s (“OCIC” or “the company”) $750 million 6.65% senior unsecured notes due March 15, 2031.

Key Points: 
  • KBRA assigns a rating of BBB to Blue Owl Credit Income Corp.'s (“OCIC” or “the company”) $750 million 6.65% senior unsecured notes due March 15, 2031.
  • KBRA believes that the company’s targeted leverage metrics allow OCIC to absorb increased volatility in less favorable market conditions.
  • The company’s investment strategy coincides with the strategies of Blue Owl Capital Corporation (KBRA Issuer/Senior Unsecured Debt ratings of BBB / Positive Outlook), Blue Owl Capital Corporation II (KBRA Issuer/Senior Unsecured Debt Ratings of BBB / Positive Outlook), and Blue Owl Capital Corporation III (KBRA Issuer/Senior Unsecured Debt ratings of BBB / Stable Outlook).
  • Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at www.kbra.com.

KBRA Assigns Rating to Blue Owl Capital Corporation's $600 Million 5.95% Senior Unsecured Notes Due 2029

Retrieved on: 
Thursday, January 18, 2024
Banking, Professional Services, Finance, OBDC, BDC, Business Development Company, KBRA, Positive, SPV, BBB, Blue Owl Capital, Risk, Environment, Investment, Risk management, Lisp (programming language), RIC, Outlook, Bank

KBRA assigns a rating of BBB to Blue Owl Capital Corporation's (NYSE: OBDC or "the company") $600 million 5.95% senior unsecured notes due March 15, 2029.

Key Points: 
  • KBRA assigns a rating of BBB to Blue Owl Capital Corporation's (NYSE: OBDC or "the company") $600 million 5.95% senior unsecured notes due March 15, 2029.
  • OBDC maintains solid access to the capital markets with a diversified funding mix of secured bank facilities, CLOs, and senior unsecured debt.
  • The company is managed by Blue Owl Credit Advisors LLC, an indirect subsidiary of Blue Owl Capital,Inc.
  • The company’s investment strategy coincides with the strategies of Blue Owl Capital Corporation II (KBRA Issuer/Senior Unsecured Debt ratings of BBB/Positive Outlook), Blue Owl Capital Corporation III (KBRA Issuer/Senior Unsecured Debt ratings of BBB/Stable Outlook), and Blue Owl Credit Income Corp. (KBRA Issuer/Senior Unsecured Debt ratings of BBB/Stable Outlook).